Anteris Technologies Global Corp. (AVR) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-13

Key Insights

Anteris filed Q1 2026 financial results (quarter ended March 31, 2026) with unaudited financial information, indicating routine quarterly reporting rather than material operational developments or surprises.
The company is an emerging growth company on NASDAQ (AVR), based in Australia with headquarters in Toowong, QLD, suggesting exposure to both US and international markets with potential currency and regulatory considerations.
The 8-K explicitly states that the furnished exhibits are not deemed filed under Section 18 of the Exchange Act and are not incorporated by reference into other filings, limiting the legal materiality of this disclosure for securities law purposes.

Want the newest filings?

This analysis covers the filing from 2026-05-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-13

Susan Knight brings significant financial expertise and audit committee experience from her tenure as Board Chair and Audit Committee Chair at Surmodics, Inc., plus prior CFO roles at MTS Systems and Honeywell, strengthening governance capabilities.
Stephen Denaro rejoins the Board with existing institutional knowledge of the company's strategic priorities and serves as Company Secretary for Australian subsidiaries, suggesting continuity and operational efficiency.
The appointments include substantial equity compensation ($250,000 initial grant for Knight plus $125,000 annual grants for both directors) aligned with Non-Employee Director Policy, indicating commitment to attract and retain experienced board members.
Ms. Knight's appointment to the Audit and Risk Committee directly addresses governance needs in a critical area, particularly relevant for a medical device company with regulatory considerations.

Filed: 2026-04-29

Anteris is discontinuing its development partnership with v2v medtech after completing Stage 1, indicating a strategic pivot away from this technology collaboration and requiring a $400,000 break fee payment.
The company retains optionality through v2v's shareholders who can either buy out Anteris' equity stake at cost or reduce it to minority ownership, creating uncertainty around the final financial and ownership structure of the investment.
Management explicitly stated the termination is not expected to have a material adverse effect on financial position or liquidity, suggesting this was a planned strategic decision rather than a forced exit due to financial stress.

Filed: 2026-02-27

Anteris Technologies Global Corp. (AVR) filed its fiscal year 2025 financial results, reporting audited financial information for the year ended December 31, 2025.
The filing includes an ASX Announcement and Results Announcement, which provide details on the company's financial performance and position for the reported period.
As an emerging growth company, Anteris may be able to take advantage of certain accommodations in financial reporting and compliance under securities laws.

Filed: 2026-01-22

Anteris Technologies is raising approximately $320 million through a public offering and private placement, which will support the next stage of growth and advance the execution of the company's clinical strategy, including the ongoing PARADIGM Trial for the DurAVR® Transcatheter Heart Valve and expansion of manufacturing capabilities.
The company has entered into a material definitive agreement with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc, to issue and sell 15,652,173 shares of common stock in a private placement for approximately $90 million.
Anteris Technologies has granted the underwriters a 30-day option to purchase up to an additional 5,217,391 shares of common stock, which the underwriters have exercised in full.

Filed: 2026-01-22

Anteris Technologies Global Corp. (AVR) has announced a strategic investment from Medtronic plc, a major medical device company, which could provide significant growth opportunities and commercial synergies for Anteris.
The investment from Medtronic, a well-established industry player, may validate Anteris' technology and product pipeline, potentially boosting investor confidence in the company's future prospects.
The partnership with Medtronic could enhance Anteris' access to global markets, distribution channels, and clinical expertise, accelerating the commercialization of its medical devices.

Other reports for Anteris Technologies Global Corp.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.